<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HD7098AED04914BEA9725D2FEBCF35E1C" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5725 IH: Benefit Evaluation of Safe Treatment Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5725</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180509">May 9, 2018</action-date><action-desc><sponsor name-id="R000580">Mr. Roskam</sponsor> (for himself, <cosponsor name-id="S001156">Ms. Sánchez</cosponsor>, <cosponsor name-id="S000364">Mr. Shimkus</cosponsor>, and <cosponsor name-id="R000599">Mr. Ruiz</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services to submit to Congress a report on the extent
			 to which Medicare Advantage plans offered under part C of the Medicare
			 program include supplemental health care benefits designed to treat or
			 prevent substance use disorders.</official-title></form>
	<legis-body id="H7F2E0BC17DA5413EBC970D41E6428B8F" style="OLC">
 <section id="H97B37C7A92BE4C9087F82B486405DE2D" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Benefit Evaluation of Safe Treatment Act of 2018</short-title></quote> or the <quote><short-title>BEST Act of 2018</short-title></quote>.</text> </section><section id="HB02DAED870E34711806AAEB684BA0611"><enum>2.</enum><header>Studying the availability of supplemental benefits designed to treat or prevent substance use disorders under Medicare Advantage plans</header> <subsection id="H38AA10E3C9344297814143E361FC43A0"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the <quote>Secretary</quote>) shall submit to Congress a report on the availability of supplemental health care benefits (as described in section 1852(a)(3)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-22">42 U.S.C. 1395w–22(a)(3)(A)</external-xref>)) designed to treat or prevent substance use disorders under Medicare Advantage plans offered under part C of title XVIII of such Act. Such report shall include the analysis described in subsection (c) and any differences in the availability of such benefits under specialized MA plans for special needs individuals (as defined in section 1859(b)(6) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-28">42 U.S.C. 1395w–28(b)(6)</external-xref>)) offered to individuals entitled to medical assistance under title XIX of such Act and other such Medicare Advantage plans.</text>
 </subsection><subsection id="H981F6ED50FC54ABC93D74F25616DB113"><enum>(b)</enum><header>Consultation</header><text>The Secretary shall develop the report described in subsection (a) in consultation with relevant stakeholders, including—</text>
 <paragraph id="H397688353C00477E9C218777D7006135"><enum>(1)</enum><text>individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act;</text>
 </paragraph><paragraph id="H2AA8C26CA1334660A404F2B1B4B9F8D4"><enum>(2)</enum><text>entities who advocate on behalf of such individuals;</text> </paragraph><paragraph id="HBB0F84031BA44AAB84D87F13D6D6FFF8"><enum>(3)</enum><text>Medicare Advantage organizations;</text>
 </paragraph><paragraph id="H8334D1A1CB7F4FCE8180CE17806B763D"><enum>(4)</enum><text>pharmacy benefit managers; and</text> </paragraph><paragraph id="H536FB073B62E4CC2A62BDF649A4A2B48"><enum>(5)</enum><text>providers of services and suppliers (as such terms are defined in section 1861 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>)).</text>
 </paragraph></subsection><subsection id="H6F50DE02972D4B849070B5BA0737C850"><enum>(c)</enum><header>Contents</header><text>The report described in subsection (a) shall include an analysis on the following:</text> <paragraph id="HF530C2D8696B4EEB97AC238B6C5EC729"><enum>(1)</enum><text>The extent to which plans described in such subsection offer supplemental health care benefits relating to coverage of—</text>
 <subparagraph id="H1E5123C5F18749EFA319310C4C7F07D8"><enum>(A)</enum><text>medication-assisted treatments for opioid use, substance use disorder counseling, peer recovery support services, or other forms of substance use disorder treatments (whether furnished in an inpatient or outpatient setting); and</text>
 </subparagraph><subparagraph id="H9F0E719B3942469A93A9A14043BD5E4E"><enum>(B)</enum><text>non-opioid alternatives for the treatment of pain.</text> </subparagraph></paragraph><paragraph id="HE9794A211F604A8CA13067C9C9678CE4"><enum>(2)</enum><text>Challenges associated with such plans offering supplemental health care benefits relating to coverage of items and services described in subparagraph (A) or (B) of paragraph (1).</text>
 </paragraph><paragraph id="H25A65C655C4A4C529850D0352248176F"><enum>(3)</enum><text display-inline="yes-display-inline">The impact, if any, increasing the applicable rebate percentage determined under section 1854(b)(1)(C) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-24">42 U.S.C. 1395w–24(b)(1)(C)</external-xref>) for plans offering such benefits relating to such coverage would have on the availability of such benefits relating to such coverage offered under Medicare Advantage plans.</text>
 </paragraph><paragraph id="H5C6E15FA5EC1416BA542DE2C43B5C815"><enum>(4)</enum><text display-inline="yes-display-inline">Potential ways to improve upon such coverage or to incentivize such plans to offer additional supplemental health care benefits relating to such coverage.</text>
				</paragraph></subsection></section></legis-body></bill>


